Apollo Global Management Ord Shs (APO) Stock Price Today
Aura AI Summary
Key Stats
- $69.38BMarket Cap
- -Volume
- FinancialsSector
- $156.0552W High
- $100.3052W Low
- -Typical Hold Time
- -$168.19BEnterprise Value
- 1.87%Div Yield
- -Trading Activity
Track Apollo Global Management Ord Shs (APO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Apollo Global Management Ord Shs has traded between a low of $100.3 and a high of $156.05, highlighting its annual price range. Buy and sell Apollo Global Management Ord Shs shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Most Recent News
Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Alamar Biosciences launches national study analyzing 21,000 plasma samples to advance Alzheimer's biomarkers.
Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...

Alamar Biosciences launches national study using blood tests to advance Alzheimer's biomarker research.
Alamar Biosciences has partnered with leading U.S. universities to launch a nationwide proteomics study analyzing around 21,000 plasma samples from 10,000 Alzheimer's and related dementia patients. Using its NULISAseq™ Neuro 220 test kit, the project...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.